



## Pathogenesis and Treatment of Preeclampsia

Guest Editors:

**Dr. Patrizia Vergani**

Department of Obstetrics and  
Gynecology, University of Milano-  
Bicocca, 20900 Monza, Italy

**Dr. Valentina Giardini**

Department of Obstetrics and  
Gynecology, IRCCS San Gerardo  
dei Tintori Foundation, University  
of Milano-Bicocca, 20900 Monza,  
Italy

Deadline for manuscript  
submissions:

**31 August 2024**

### Message from the Guest Editors

Preeclampsia is a pregnancy-specific hypertensive disorder with multisystem involvement. It is one of the “great obstetrical syndromes” with multiple etiologic factors that converge to an angiogenic imbalance, such as endothelial dysfunction.

Preeclampsia complicates 5–8% of pregnancies worldwide and is one of the main causes of maternal and perinatal morbidity and mortality. Despite the increase in knowledge of its pathogenesis, there is no specific cure for this disease, other than delivery. Therefore, there is an urgent need for therapeutic strategies to prolong pregnancy in the case of early-onset forms and to prevent/reduce maternal–fetal–neonatal complications.

This Special Issue aims to collate research that explores all potential therapies for the prevention and treatment of preeclampsia, in the light of new etiopathogenetic evidence.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research

Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA

2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](#)